# Lidocaine Mucilage-ICG as an Optical Agent for Tumor Delineation During Breast-conserving Surgery

> **NCT04438577** · NA · UNKNOWN · sponsor: **Shantou Central Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Lidocaine mucilage-ICG

## Key facts

- **NCT ID:** NCT04438577
- **Lead sponsor:** Shantou Central Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-20
- **Primary completion:** 2021-07
- **Final completion:** 2024-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04438577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04438577, "Lidocaine Mucilage-ICG as an Optical Agent for Tumor Delineation During Breast-conserving Surgery". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04438577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*